David Moller has joined Sigilon Therapeutics to become the company’s chief scientific officer. Moller comes to the Cambridge, MA, drug developer from Eli Lilly (NYSE: LLY), where he was vice president of business development for emerging technology and innovation. Last year, Sigilon raised $23.5 million in a Series A financing round to bring its technology for encapsulating therapeutic proteins into clinical testing.
UNDERWRITERS AND PARTNERS
Click to view a price quote on CNTF.
Click to research the Computer Hardware industry.Jean-Paul Kress has been appointed president and CEO of Syntimmune. Kress will also serve as a director of the New York-based drug developer. He replaces David de Graaf, who has stepped down as CEO and a member of the company’s board of directors. Kress comes to Syntimmune from Cambridge, MA-based Biogen (NASDAQ: BIIB), where he was executive vice president and president, international. He was also head of Biogen’s global therapeutic operations. Syntimmune’s lead compound, SYNT001, is an antibody drug in early-stage clinical trials as a treatment for autoimmune disorders.
UNDERWRITERS AND PARTNERS
Peter Ho is joining Boston Pharmaceuticals as chief medical officer. He comes to the Cambridge, MA-based drug developer from Epizyme (NASDAQ: EPZM), where he also served as chief medical officer. His experience includes posts at Johnson & Johnson (NYSE: JNJ), the National Cancer Institute, Novartis (NYSE: NVS), and DuPont Pharmaceuticals.
UNDERWRITERS AND PARTNERS
OncoResponse has named Anil Singhal chief scientific officer of the Houston-based cancer drug developer. He comes to the company from AbbVie (NASDAQ: ABBV), where he was vice president, early oncology development. OncoResponse has also appointed Kamal Puri vice president of research and development. Puri was most recently director, immunology & inflammation, at Celgene (NASDAQ: CELG). OncoResponse is preparing to start clinical trials testing its lead antibody drug, ONCR-201.
UNDERWRITERS AND PARTNERS
Imbed Biosciences has raised a funding round of nearly $1.6 million, which the Fitchburg, WI-based startup plans to use to begin selling an ultra-thin wound dressing material later this year, CEO Ankit Agarwal says.
Imbed has been working to commercialize the dressing, which is known as Microlyte Ag, for years. It’s underpinned by nanofilm technology that uses silver’s antimicrobial properties to kill infection-causing pathogens, helping wounds heal in a way that does not require treatment with potentially harmful levels of the metal.
On its website, Imbed claims that Microlyte Ag contains anywhere from a dozen to hundreds of times less… Read more »
UNDERWRITERS AND PARTNERS
Life science companies are continuing to raise cash, keeping pace with the financing trends of recent years.
Fourth quarter figures are still being tallied but in the third quarter, 171 companies raised $3.2 billion, according to the Healthcare Moneytree report from PricewaterhouseCoopers and CB Insights. Those totals compare to 166 companies that raised $3.3 billion in the same period in 2016. Two years ago, the Moneytree report listed $3 billion raised from 210 deals in the third quarter.
On the first business day of 2018, several companies announced new rounds of financing to support new products coming to market or clinical… Read more »
UNDERWRITERS AND PARTNERS
Click to view a price quote on FEYE.
Click to research the Computer Software & Services industry.If you happen to be a world-famous futurist, inventor, and entrepreneur, what would compel you to take a corporate job? That was one of the questions that I discussed with Ray Kurzweil recently at Synergy Global Forum in New York. Kurzweil was among a large group of luminaries who shared their ideas on innovation and the future with an audience of 5,000 at the conference’s North American debut at Madison Square Garden. I had the pleasure of moderating a Q&A session with the audience following Kurzweil’s presentation. We’ve talked about a great many things, from his views on strong AI to… Read more »
UNDERWRITERS AND PARTNERS
